
Q-Line Biotech IPO Details
Last Updated on May 21, 2026 Q-Line Biotech Ltd. IPO Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of
Incorporated in May 2015, Autofurnish Ltd is engaged in manufacturing and trading automotive accessories.The company mainly operates in the B2B segment, focusing on the design, manufacturing, marketing, and sale of automobile accessories
Such as body covers and foot mats for cars and two-wheelers. Its products are sold under the “Autofurnish” and “Mototrance” brands. The company’s facilities are ISO- and GMP-certified, ensuring quality and safety.
Golden Mace Private Limited and its subsidiary operate in the B2C segment through online platforms such as Amazon, Flipkart, Zepto, and its own website.
The company’s manufacturing facilities are certified under ISO 9001:2015, ISO 14001:2015, ISO 50001:2018, ISO 45001:2018, ISO 26262-1:2011, IATF 16949:2016, and GMP, demonstrating our commitment to quality, safety, and sustainability.
The company makes motorcycle utility and rider products like Towel Cloths, polishing pads, riding gear, and accessories, focusing on durability, functionality, and convenience.
As of March 31, 2026, the company had 40 employees.
Competitive Strengths
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 33.50 | 23.28 | 16.01 | 14.11 |
| Total Income | 28.32 | 33.88 | 15.92 | 10.60 |
| Profit After Tax | 2.83 | 3.50 | 1.63 | 0.16 |
| EBITDA | 4.79 | 5.11 | 2.82 | 0.85 |
| NET Worth | 17.57 | 14.71 | 9.07 | 7.50 |
| Reserves and Surplus | 7.61 | 4.76 | 8.56 | 6.99 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capital Expenditure-Purchase of new machineries | 1.89 |
| 2 | Working Capital | 9.50 |
| 3 | General Corporate Purposes | 1.96 |
| 4 | Issue Expenses | 1.45 |
| Total | 14.80 |
| KPI | Dec 31, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 16.09% | 23.50% |
| ROCE | 21.34% | 33.74% |
| Debt/Equity | 0.61 | 0.36 |
| RoNW | 16.09% | 23.50% |
| PAT Margin | 9.99% | 10.51% |
| EBITDA Margin | 16.93% | 15.30% |
| Price to Book Value | 2.32 | 2.77 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 3.52 | 2.79 |
| P/E (x) | 11.64 | 14.7 |
| IPO Date | 21 to 25 May, 2026 |
| Listing Date | Fri, May 29, 2026T |
| Face Value | ₹10 per share |
| Issue Price | ₹41 per share |
| Lot Size | 3,000 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Fixed Price IPO |
| Listing At | BSE SME |
| Total Issue Size | 35,61,000 shares (agg. up to ₹15 Cr) |
| Reserved for Market Maker | 1,80,000 shares (agg. up to ₹0.7380 Cr) |
| Fresh Issue (Ex Market Maker) | 33,81,000 shares (agg. up to ₹14 Cr) |
| Net Offered to Public | 33,81,000 shares (agg. up to ₹14 Cr) |
| Share Holding Pre Issue | 99,54,508 shares |
| Share Holding Post Issue | 1,35,15,508 shares |
Mr. Puneet Arora and Mr. Ruppal Wadhwa are the company promoters.
| Share Holding Pre Issue | 93.10% |
| Share Holding Post Issue | 68.57% |
As per our analysis and Based on the information we have, this is the output.
Allah knows best.
If you find this result mistaken or questionable, let us know via email at info (@) halalstock.in
The IPO dashboard offers insights on the Latest Current & Upcoming IPOs in BSE & NSE. It also evaluates IPOs for Shariah compliance, ensuring alignment with Islamic principles for ethical investment choices.

Last Updated on May 21, 2026 Q-Line Biotech Ltd. IPO Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of

Last Updated on May 21, 2026 Autofurnish Ltd. IPO Incorporated in May 2015, Autofurnish Ltd is engaged in manufacturing and trading automotive accessories.The company mainly operates in the B2B segment,

Last Updated on May 20, 2026 Bio Medica Laboratories Ltd. IPO Incorporated in August 2015, Bio Medica Laboratories specialises in manufacturing pharmaceutical parenteral formulations, producing a wide range of ethical
You can contribute as little as
100, 200, 500 & so…
every bit counts.